
Unravelling a novel pathway in the human hypothalamus involved in body weight regulation in obesity. (NORMALISE)
Can we stop weight regain after obesity treatment?
Project Overview
Obesity is a global health crisis linked to diabetes, heart disease, and other serious conditions. Current treatments, like GLP-1 agonists (e.g., Wegovy, Ozempic), have limitations, including high costs, injections, muscle loss, and weight regain after stopping treatment. In collaboration with Tanai Therapeutics, this project explores new ways to regulate body weight, aiming for long-lasting, more effective obesity treatments with fewer side effects.
Societal and Economic Relevance
Over a billion people worldwide suffer from obesity, significantly increasing healthcare costs. Obesity-related diseases could cost trillions globally in the coming years. New treatments could reduce this burden, improve public health, and enhance quality of life. In the short term, this project will drive innovation in biotech and pharmaceuticals. Long-term, it could lower healthcare costs, expand treatment accessibility, and create jobs in drug development and manufacturing.
Project Approach and Innovation
This study investigates how brain networks, particularly interactions between neurons and immune microglia in the hypothalamus, regulate body weight. Our findings reveal differences in neuron-glia interactions between lean and obese states, suggesting a critical role of neuroimmune crosstalk in metabolic control. By analyzing human brain tissues containing all cell types and utilizing advanced obesity models, this research aims to identify key mechanisms that drive weight loss and prevent regain. Unlike current therapies that focus on temporary weight reduction, this project seeks long-term interventions targeting the underlying neurobiological processes of obesity.
Expected Outcomes and Deliverables
This project will generate valuable insights into weight regulation, supporting the development of more sustainable obesity treatments. Findings will help Tanai Therapeutics advance new therapies, potentially transforming obesity care and improving health worldwide.

Andere projecten
In elk PPS-project werken kennisinstellingen, bedrijven en zorgpartijen samen aan een concrete gezondheidsvraag. Bekijk het volledige projectoverzicht.
Bekijk de programma’s
Binnen onze programma’s werken bedrijven, kennisinstellingen en regionale partners samen aan innovaties die bijdragen aan betere gezondheid en zorg.
Bekijk de partnerschappen
Strategische publiek-private partnerschappen (PPP's) zijn meerjarige samenwerkingen tussen bedrijven, kennisinstellingen en andere partijen.






